Figure 2 Clinical course and response to therapy in 6 Australian patients with HMGCR antibodies The clinical course, creatine kinase (CK) levels, Medical.

Slides:

Advertisements

Similar presentations

Statin Induce Myotoxicity

Advertisements

Exacerbations. Exacerbations An exacerbation of COPD is an acute event characterized by a worsening of the patient’s respiratory symptoms that is beyond.

Carrie M. Hersh, D.O., Robert Fox, M.D.

Four Known Types of MS Clinically isolated syndrome (CIS)

A 26-y.o. woman with RRMS and eruption of plaques.

Figure 2. Infliximab treatment effect

Figure 1 Percentages of patients with first seizure experiencing a recurrent seizure over time This graph is based on a fixed-effect pooled percentage.

Pain Management: Patients Maintained on Buprenorphine

Figure 1 Muscle biopsy from a patient with a slowly progressive (24 years) HMGCR antibody–associated myopathy syndrome (A) Hematoxylin & eosin stain, (B)

Hidradenitis Suppurativa

Figure 2 Disease progression slowed during each round of Treg infusions and correlated with increased Treg suppressive function Disease progression slowed.

Figure Brain MRI of the patient throughout the disease course(A) Brain MRI at the time of cerebral toxoplasmosis diagnosis (a) and after 1 month of toxoplasmosis.

Figure 2 Temporal distribution of MOG antibody in serum of 2 relapsing patients with demyelinating diseases Temporal distribution of MOG antibody in serum.

Figure Clinical course of acute neuritis and NMDA receptor (NMDAR) encephalitis, sural nerve biopsy, and detection of NMDAR antibodies(A) Approximately.

Figure 1 Comparison of miR-150-5p (log scale), prednisone dose (mg), and QMG score between the thymectomy (ETTX) and prednisone groups Comparison of miR-150-5p.

Figure 3 Example of venous narrowing

Figure 2 NMDAR-Ab levels, clinical syndromes, and therapy in 8 informative patients with white matter syndromes in association with NMDAR-Ab NMDAR-Ab levels,

Figure 1 Cerebral MRI during the disease course Cerebral MRI with multiple cerebral supratentorial lesions during the disease course: periventricular lesions.

Figure 1 MOR103 sequential-dose trial flowchart of study population with multiple sclerosis aPatients received 2 doses of study drug before trial withdrawal.

Figure 1 8-Iso-PGF2α levels in CSF of patients with MS and controlsCSF 8-iso-prostaglandin F2α (8-iso-PGF2α) levels were estimated using an ELISA. (A)

Figure 3 EEG demonstrating ictal seizure discharges in a patient with faciobrachial dystonic seizures The EEG of a 56-year-old woman with faciobrachial.

Figure 2 Overview of the patient's history and immunofluorescence pattern of patient CSF IgG Overview of the patient's history and immunofluorescence pattern.

Figure 1 Characteristics of the German National MS Cohort

Figure 3 Clinical outcome of apheresis therapies for NMOSD attacks

Figure 2 JCV index JCV index (A) Fifty samples of natalizumab-treated patients with multiple sclerosis were assessed twice for their anti-JCV antibody.

Figure 2 Example of venous narrowing

Figure 1 Evolution of blood cell counts during 18-month treatment and follow-up (A) Mean white blood cell count, (B) mean lymphocyte count, (C) mean eosinophil.

Figure 4 Pattern of relapse in patients with MOG-Ab Five myelin oligodendrocyte glycoprotein antibody (MOG-Ab)–positive patients experienced a relapse,

Figure 4 Aquaporin-4 immunoglobulin G (AQP4-IgG) index in time-matched paired serum-CSF specimens: 3 attack/preattack pairs and 7 bridge/remission pairs.

Figure 2 Abnormal myofiber nuclei in HMGCR antibody–associated myopathy Myonuclei are often enlarged (dark arrow) with clear centers (dark arrowhead) or.

Figure 1 JCV serostatus JCV serostatus (A) Serostatus of 1,921 natalizumab-treated patients with multiple sclerosis, with JCV− patients shown in black.

Figure 5 Pairwise correlations between selected patient-reported outcomes and performance tests in patients with MS (A) The number of pairwise correlations.

Figure 2 Individual EDSS scores

Figure 4 Laquinimod treatment suppresses development of spontaneous EAE Laquinimod treatment suppresses development of spontaneous EAE (A) 2D2 × Th mice.

Figure Clinical and radiologic course(A) The T2 contrast-enhanced sequence on day 3 shows an extensive central cord lesion extending from C2 to T7. Clinical.

Figure 1 Responder rates of patients at 4 weeks compared with prevaccinated levels Responder rates of patients at 4 weeks compared with prevaccinated levels.

Figure 2 Relative concentration (in mAb equivalents) of JCV Ab in samples tested prior to IVIg (“pre-IVIg”), within 30 days of IVIg (“during IVIg”), and.

Figure 1 Flowchart of patient inclusion

Figure 1 Annual trend in specimen type submitted as first sample for aquaporin-4 immunoglobulin G testing (serum only vs CSF only vs both) from 101,065.

Figure 1 Imaging of disease onset and treatment response Repeat MRI scans including fluid-attenuated inversion recovery (FLAIR) (A) and T2 fast field echo.

Figure 1 Relapse and rituximab historyThe figure shows rituximab (RTX) treatment history as well as relapse history for 100 days prior to the first RTX.

Figure 2 Clinical and autoantibody status of 2 CNTN1 or NF155+ patients not receiving rituximab Despite corticosteroids and methotrexate treatment, patient.

Figure Disease course and neuropathology of CASPR2 encephalitis(A) Summary of the most important changes during the disease course. Disease course and.

Figure 3 Pedigrees of 3 multiplex families with NLRP3 mutations and MS The patient numbers refer to the patients listed in table 1. Pedigrees of 3 multiplex.

Figure 2 Summary of the utility of MOG-Abs and OCB testing in predicting pediatric disease course at onset compared to clinical follow-up at 1 yearFollowing.

Figure 1 Clinical status and autoantibody titers in rituximab-treated patients with anti-CNTN1/NF155 chronic inflammatory demyelinating polyneuropathy.

Figure Imaging, histology/immunohistochemistry, and schematic course of treatment with corresponding clinical and radiologic disease activity Imaging,

Figure 2 Correlation between wGRS and age at onset The figure shows the correlation between weighted genetic risk score (wGRS) and age at onset in all.

Figure 2. Patient stratification by the reported duration of symptoms and disease severity at the time of assessment Patient stratification by the reported.

Figure 2 Assessment of systemic disease activityTc99 scintigraphy (A) and fluorodeoxyglucose PET imaging (B, C) at disease onset 2 years before acute deterioration.

Figure Forty-two months of follow-up of clinical symptoms in parallel with therapeutic interventions and antibody titers/B-cell count Forty-two months.

Figure 4. The N:M ratio is significantly increased in patients with ALS and correlates with disease progression The N:M ratio is significantly increased.

Figure. Model supporting noradrenergic signaling in stiff-person syndrome (SPS) pathophysiology and clinical exacerbations Model supporting noradrenergic.

Figure Avidity of IgG specific for influenza A and B following flu vaccinationAvidity of immunoglobulin (Ig) G specific for influenza A and B before and.

Figure 4 Four representative disease-course archetypes

Figure 3 Effect of IVIg on endogenous relative concentration (in mAb equivalents) of JCV AbSix patients shown in this figure have had John Cunningham virus.

Figure 1 Peripheral blood lymphocyte counts during dose titrationB-lymphocyte (CD19+; A) and total lymphocyte (CD45+; B) counts (cells/µL) in peripheral.

Figure Clinical course and overview of the treatment protocols♦ = neuroradiologic evidence of new disease activity; ★ = CD19+ reconstitution. Clinical.

Figure 2 Assessment of fluctuation in fatigue scores using environmental data The relationship between fatigue (as measured by the Modified Fatigue Impact.

Figure 1 Follow-up periods of 33 anti–3-hydroxy-3-methylglutaryl coenzyme A reductase autoantibody (HMGCR Ab+) myopathy patients in relation to cancer.

Figure 6 Multiple target epitopes exist in the N-terminal domains of Caspr2 (A) Multidomain deletion constructs of Caspr2 were generated to determine which.

Algorithm based on the 2015 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) recommendations for the management of polymyalgia.

Figure A 57-year-old man with relapsing-remitting MS (RRMS) and new-onset ataxia A 57-year-old man with relapsing-remitting MS (RRMS) and new-onset ataxia.

Figure 2 Clinical data and variation of sNfL levels of patients 4–6 with ATZ-treated MS Clinical data and variation of sNfL levels of patients 4–6 with.

Figure 4 Cell count of selective immune cell subpopulations during alemtuzumab Cell count of selective immune cell subpopulations during alemtuzumab Absolute.

Current standard of care treatment protocols for LN induction therapy.

Figure 1 Numbers/seropositivity rates of IVIg-naive and IVIg-exposed STRATIFY-2 enrollees* = % of enrollment samples, ** = date of IVIg and/or concentration.

Figure 2. Percentage of CD16− monocytes in the blood is reduced during disease progression Percentage of CD16− monocytes in the blood is reduced during.

Therapy of adult ITP before splenectomy.

Figure (A and B) Effect of canakinumab in muscle strength measured in each patient as mean bilateral GF (A) and TMS (B) during the mean study period of.

Presentation transcript:

Figure 2 Clinical course and response to therapy in 6 Australian patients with HMGCR antibodies The clinical course, creatine kinase (CK) levels, Medical Research Council (MRC) scale for power grading of shoulder abduction strength (appendix e-1 at Neurology.org/nn), and therapeutic regimens in the 6 patients in this cohort are graphically represented. Clinical course and response to therapy in 6 Australian patients with HMGCR antibodies The clinical course, creatine kinase (CK) levels, Medical Research Council (MRC) scale for power grading of shoulder abduction strength (appendix e-1 at Neurology.org/nn), and therapeutic regimens in the 6 patients in this cohort are graphically represented. Timing of statin commencement and cessation are indicated. Horizontal arrows indicate the duration of use of various immunosuppressive therapies. All patients were asymptomatic with no reported weakness at the time of statin commencement based on assessment by their general practitioner. Most patients experienced relapses with attempts to wean steroids, with a rise in CK often preceding clinical weakness. (A) Illustrative case 1 (case 1, table). The CK levels of this 60-year-old man are graphed from the time of statin commencement through 93 months of follow-up. Acute relapses characterized by worsening proximal weakness and coinciding with a rise in CK accompanied attempts to wean the dose of oral prednisone below 10 mg daily. Reinstitution of steroids and the use of IV immunoglobulin (IVIg) had a good correlation with clinical improvement and a reduction in CK. (B) Illustrative case 2 (case 2, table). The CK levels of this 73-year-old woman are shown for 30 months of follow-up. Early recognition of this diagnosis and initiation of high-dose prednisone and methotrexate (MTX) resulted in a rapid improvement in CK and clinical resolution of weakness. A slow and cautious approach to weaning steroids was associated with clinical remission without any relapses, and maintenance immunosuppression with prednisone 5 mg once daily and MTX 20 mg weekly has resulted in clinical stabilization. (C) Case 3, table. This 66-year-old woman was on a statin for 24 months prior to symptom onset. Early treatment with statin cessation and high-dose steroids resulted in an immediate improvement, but rapid steroid tapering prompted a severe relapse necessitating respiratory support and multiple immunosuppressive agents to allow for clinical stabilization. (D) Case 4, table. This 74-year-old woman responded well to steroid therapy, but attempts to wean steroids prompted relapses associated with both a CK rise and clinical weakness. Maintenance therapy with prednisone and IVIg has allowed for clinical remission. (E) Case 5, table. This 77-year-old man was on a statin for 1 year prior to symptom onset. Initial therapy with steroids, IVIg, and MTX allowed for an early recovery. However, a rechallenge with statin therapy prompted a further relapse. This patient required multiple immunosuppressive agents to maintain remission, with attempts to wean prednisone below 15 mg prompting 2 further relapses and ongoing disease activity almost 11 years after statin cessation. Maintenance therapy with prednisone and IVIg has permitted clinical remission. (F) Case 6, table. This 69-year-old man was on a statin for 2.5 years prior to symptom onset. He responded well to treatment with prednisone, IVIg, and MTX. Steroids were weaned due to his significant vascular comorbidities, and he was maintained on MTX. Recent results herald a possible early relapse, with CK levels trending up and mild clinical weakness, suggesting reinstitution of steroid therapy may be required. HMGCR = 3-hydroxy-3-methylglutaryl-coenzyme A reductase; IV MP = IV methylprednisolone; PE = plasmapheresis. Sudarshini Ramanathan et al. Neurol Neuroimmunol Neuroinflamm 2015;2:e96 © 2015 American Academy of Neurology